In conclusion, blockade of SETDB1 could enhance specific cytotoxic T-cell responses against tumor by not only activating immunostimulatory genes but also encoding retroviral antigens and generating MHC-I peptides as neoantigens, proposing SETDB1 as a highly potential target to synergize with ICB therapy. This evidence concerns the gene SETDB1 and neoplasm.